TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06190145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
Study: NCT05067972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07260437
Description: B7-H4 x CD3 bi-specific mAb
Study: NCT04557618

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Vagus nerve Stimulation
Description: Transcutaneous auricular vagal nerve ear clip applied without current
Study: NCT06397391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TREM-AB
Description: Wearing medical device on site during 1 hour
Study: NCT06132685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT05067972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07260437
Description: B7-H4 x CD3 bi-specific mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07260437
Description: B7-H4 x CD3 bi-specific mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07260437
Description: B7-H4 x CD3 bi-specific mAb

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: B7-H4 IHC
Description: B7-H4 expression

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: B7-H4 IHC
Description: B7-H4 expression

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: B7-H4 IHC
Description: B7-H4 expression
Study: NCT05318716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat grafting - Revolve device
Description: Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat grafting - Revolve device
Description: Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat grafting - Decantation
Description: Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fat grafting - Decantation
Description: Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
Study: NCT05189288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T
Study: NCT06132685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given dexamethasone or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given dexamethasone or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04633889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (240mL) intravenous infusion over 12 hours
Study: NCT04971915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimalist footwear
Description: The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
Study: NCT05145296

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab
Description: Four consecutive cohorts each comprising 3 patients are planned. STEP I: Patients receive Belatacept 10mg/kg, administered on days 1, 5, end of week 2, 4 and 8 .~Patients without a significant decrease in the global cPRA (cPRA or TGI ≥99%) or significant reduction of anti-HLA Ab MF will continue to the second step.~STEP II: (15 weeks) One week after the last injection of belatacept, patients will undergo 4 sessions of apheresis (plasmapheresis (PF) or Immunoadsorption (IA)) which will be given every 48h. At week 11, patients will receive 4 doses of daratumumab (8mg/kg) every two weeks until week 17. Daratumumab will be alternated with 4 additional doses of belatacept 5 mg/kg FOLLOW-UP (24 weeks) All patients exiting the study, either having completed all treatment courses or exiting prematurely (transplanted or not), will be proposed monthly follow-up visits
Study: NCT06114446

Intervention type: OTHER
Group type: OTHER
Intervention: simulation group
Description: Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersive virtual reality
Description: Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery

Intervention type: OTHER
Group type: OTHER
Intervention: observation
Description: All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observation
Description: All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
Study: NCT05263583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide
Description: continuous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide
Description: continuous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide
Description: continuous intravenous infusion
Study: NCT05661331

Intervention type: DEVICE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.

Intervention type: DEVICE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.

Intervention type: DEVICE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is indicated for use in the treatment of portal hypertension and its complications such as variceal bleeding and refractory ascites. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion is a current generation of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion was designed to build on the success of the GORE® VIATORR® TIPS Endoprosthesis. The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion allows for intraoperative diameter control to reach a targeted portal pressure gradient.
Study: NCT06484244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Description: Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Description: Participants will complete 5 sessions of split-belt treadmill-based locomotor adaptation. The split-belt instrumented treadmill allows the two belt speeds to be operated independently, enabling different belt speeds for each leg. The split-belt walking assessment will consist of 3 phases: baseline phase in which the belts operated at the same speed (Pre-tied, 2-minutes), a phase in which the belts operated at different speeds (Split-belt, 15-minutes), and a final phase in which the belts operated at the same speed (Post-tied, 4-minutes).
Study: NCT05193019

Intervention type: OTHER
Intervention: Parenteral antiplatelet agents
Description: Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
Study: NCT05975268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: JS005/placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: JS005/placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: JS005/placebo
Study: NCT04894604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance® Solo NPWT System
Description: Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
Study: NCT06094010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
Study: NCT05711524

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cryoprecipitate
Description: This is the cryoprecipitate already currently being given to patients with a cryo order.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pathogen-Reduced Cryoprecipitate
Description: This is the pathogen-reduced cryoprecipitate that is intended to be compared to the standard cryoprecipitate.
Study: NCT06015854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vvax001 therapeutic cancer vaccine
Description: Patients will receive three immunizations, with an interval of 3 weeks between each immunization at weeks 0, 3 and 6. Each vaccination will be given as two injections; 1 injection in each leg. The injections will be administered intramuscularly in the upper legs, preferably in the m. vastus lateralis.
Study: NCT06188780

Intervention type: DIAGNOSTIC_TEST
Intervention: urine/blood analysis with IA and LC-GCMS analysis
Description: urine/blood analysis with IA and LC-GCMS analysis
Study: NCT06192888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: IV Glofitamab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV Obinutuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Lenalidomide
Study: NCT06575218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Description: Virtual reality training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise and cognitive exercise
Description: Conventional exercise and cognitive exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study: NCT04571619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Skills Training (PCST)
Description: The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
Study: NCT06547879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Self Management Program
Description: The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
Study: NCT05344066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best NHS Care
Description: Personalised advice and support from a diabetes dietician to follow NICE healthy eating diet and physical activity recommendations for GDM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Low Energy Diet
Description: Two non-consecutive days of a food based 1000 kcal diet and five days of the NICE healthy eating diet and physical activity recommendations for the best NHS care group.
Study: NCT06546436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CARC-101C
Description: Subjects enrolled in the project will received a one-dose injection of CARC-101C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CARC-101C
Description: Subjects enrolled in the project will received a one-dose injection of CARC-101C
Study: NCT05907200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination ultrasound therapy and manual therapy
Description: The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual therapy
Description: manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
Study: NCT05105711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI coaching intervention
Description: The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
Study: NCT06485037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Self-selected 10-hour eating window for 2 months
Study: NCT05723627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
Study: NCT04978285

Intervention type: OTHER
Intervention: Anemia
Description: Depends on Day 3 Hb result

Intervention type: OTHER
Intervention: Anemia
Description: Depends on Day 3 Hb result
Study: NCT04866485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and pembrolizumab
Description: Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
Study: NCT04398524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months